All Stories
MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver cancer…
Zymergen has raised $300 million in financing. The investment total, announced yesterday, includes Series D funding led by Baillie Gifford, and joined by Baron Capital Group and one of the world’s largest sovereign wealth funds, as well as additional growth…
Korro Bio raised $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a…
Luna DNA, the first community-owned genomic and medical research database, today announced financing from key investors Illumina Ventures and Arch Venture Partners. Additional investors include UK-based Bridgelink Capital; Seattle-based Hemisphere Ventures; and Dr. Aristides Patrinos, a former leader of the Human…
